ストックスクリーナーアプリを入手
5.82
3.56%
0.20
アフターアワーズ：
5.82
前日終値:
$5.62
開ける：
$5.54
24時間の取引高:
333.47K
Relative Volume:
0.37
時価総額：
$580.88M
収益：
-
当期純損益:
$-299.80M
株価収益率:
-0.4801
EPS:
-12.1221
ネットキャッシュフロー:
$-217.49M
1週間 パフォーマンス:
-7.32%
1か月 パフォーマンス:
+16.87%
6か月 パフォーマンス:
+33.79%
1年 パフォーマンス:
-36.25%
1日の値動き範囲:
$5.43
$5.84
1週間の範囲:
$5.39
$6.47
52週間の値動き範囲:
$3.36
$9.64
Acelyrin Inc Stock (SLRN) Company Profile
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 開始されました | Wells Fargo | Equal Weight |
| 2023-12-08 | 開始されました | Citigroup | Neutral |
| 2023-09-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-30 | 開始されました | Jefferies | Buy |
| 2023-05-30 | 開始されました | Morgan Stanley | Overweight |
| 2023-05-30 | 開始されました | Piper Sandler | Overweight |
| 2023-05-30 | 開始されました | TD Cowen | Outperform |
すべてを表示
Acelyrin Inc (SLRN) 最新ニュース
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Did Acelyrin Inc (SLRN) perform well in the last session? - US Post News
Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4%Should You Sell? - MarketBeat
Acelyrin Inc (SLRN) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Up 5.9%Still a Buy? - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Millennium Management LLC Has $20.47 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Renaissance Technologies LLC Has $1.75 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLC - Defense World
Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Recent Insider Activity Suggests Potential Gains for Acelyrin Inc (SLRN) - Knox Daily
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares By Investing.com - Investing.com Australia
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - StockTitan
Acelyrin Inc (SLRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Acadian Asset Management LLC Makes New $590,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
In the Green: Acelyrin Inc (SLRN) Closes at 4.31, Up/Down -8.30 from Previous Day - The Dwinnex
Results from Acelyrin Inc (SLRN) show risk - US Post News
SLRN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Los Angeles Capital Management LLC Takes $693,000 Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance
Significant Acquisition by T. Rowe Price Investment Management i - GuruFocus.com
Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab - TipRanks
ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com Australia
Acelyrin Inc (SLRN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of - The Bakersfield Californian
Acelyrin, Inc. (NASDAQ:SLRN) Receives $10.83 Average Target Price from Analysts - MarketBeat
How does Acelyrin Inc (SLRN) change from a tortoise to a hare? - SETE News
Is it possible to buy Acelyrin Inc(SLRN) shares at a good price now? - US Post News
Acelyrin Inc (SLRN) 財務データ
収益
当期純利益
現金流量
EPS
5.11%
0.50%
大文字化:
|
ボリューム (24 時間):